Thyroid disorders encompass a wide spectrum of functional and structural pathologies, ranging from autoimmune dysregulation to malignant neoplasms. Among the systemic manifestations of autoimmune thyroid disease, Thyroid Eye Disease (TED) also known as Graves' orbitopathy (GO) is the most prominent and impactful. TED is a debilitating autoimmune condition often associated with thyroid dysfunction, leading to significant ocular and orbital morbidity. The clinical presentation of TED is highly variable; it can range from mild disease requiring observation, to sight-threatening disease requiring major drug therapy and orbital surgery [1-7].

The pathophysiology of TED is intricately linked to humoral autoimmunity. GO is caused by persistent, unregulated stimulation of TSHR-expressing orbital target cells, such as fibroblasts and pre-adipocytes. Autoantibodies directed against the thyrotropin receptor (TSHR-Ab) cross-react with these orbital tissues [4]. Upon activation, orbital fibroblasts proliferate and secrete excessive quantities of hydrophilic glycosaminoglycans (GAGs), leading to tissue edema, muscle enlargement, and subsequent proptosis [7]. Extensive research confirms that serum TSHR-Ab, specifically stimulatory antibodies (TSAb), strongly correlate with the clinical activity and severity of GO [6]. Furthermore, levels of TRAb in subjects with recent-onset GO are directly correlated with clinical activity, confirming their critical role in the disease's pathogenesis [4].

Parallel to the ocular findings, a subset of patients with severe autoimmune thyroiditis develop localized thyroid dermopathy, classically presenting as pretibial myxedema. This dermatological manifestation shares a nearly identical immunopathogenic mechanism with TED, involving the dermal accumulation of GAGs driven by TSHR-reactive T lymphocytes. Clinically, thyroid dermopathy is almost exclusively observed in patients harboring moderate-to-severe TED, acting as a cutaneous biomarker for profound systemic autoimmunity.

Despite the well-characterized medical management of TED, the relationship between these extrathyroidal manifestations and definitive surgical thyroid pathology requires further elucidation. Thyroidectomy is frequently indicated for medically refractory hyperthyroidism, compressive goiters, and suspected or confirmed thyroid malignancies. Notably, papillary carcinoma of the thyroid often has an excellent prognosis, particularly in young adults, even when lymph node involvement is present. Therefore, relatively conservative surgery may be advised in low-risk patients, whereas total or subtotal thyroidectomy is required for advanced disease or when postoperative radioactive iodine is planned [3].

Navigating the intersection of surgical oncology, endocrinology, and ophthalmology demands highly standardized clinical assessment. To that end, disease activity is standardly assessed using the Clinical Activity Score (CAS), based on classical signs of inflammation including pain, redness, swelling, and impaired function [1]. The EUGOGO classification system stratifies GO into mild, moderate-to-severe, and sight-threatening categories to guide therapeutic decision-making [2]. Measurement of functional TSHR-Ab, especially TSAb, is clinically relevant for the differential diagnosis and management of GO [4].

This prospective study was designed to systematically evaluate the clinical profile of patients undergoing thyroidectomy, meticulously documenting the relationships between preoperative TED activity (using CAS and EUGOGO standards), the presence of thyroid dermopathy, serological autoantibody titers, and the final surgical histopathology.

Study Design and Setting

This prospective observational clinical study was conducted at KBNU-Faculty of Medical Sciences; a tertiary academic medical center over a continuous 24-month period. The institutional review board approved the study protocol, which strictly adhered to the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment, multidisciplinary evaluation, and surgical intervention.

Patient Cohort Standardization

To maintain statistical rigor and uniform data processing, the study cohort was standardized to a definitive sample size of 85 consecutive adult patients (N=85).

Inclusion Criteria:

• Patients aged ≥ 18 years.
• Scheduled for total or completion thyroidectomy for indications including medically refractory Graves' disease, toxic multinodular goiter, or suspected/confirmed thyroid malignancy based on fine-needle aspiration cytology (FNAC).
• Completion of a standardized preoperative evaluation by Endocrine Surgery, Ophthalmology, and Dermatology.

Exclusion Criteria:

• Prior orbital decompression surgery or localized orbital radiotherapy.
• History of previous neck surgery or radioactive iodine therapy.
• Co-existing non-thyroidal autoimmune orbital disease or active orbital infection.

Multidisciplinary Clinical Pathway

Ophthalmic Evaluation:

All patients underwent a comprehensive preoperative ophthalmic examination. The inflammatory status of the orbit was quantified. Active GO is defined clinically by a CAS of 3 or greater [1]. The 7-item CAS evaluates spontaneous retrobulbar pain, pain on eye movement, eyelid erythema, conjunctival erythema, chemosis, swelling of the caruncle, and eyelid edema [1].

Following activity scoring, disease severity was categorized based on the EUGOGO classification [2]:

• Mild GO: Minor impact on daily life, eyelid retraction < 2 mm, mild soft tissue involvement, and exophthalmos < 3 mm above normal.
• Moderate-to-Severe GO: Without sight-threatening features but sufficient impact on daily life to justify immunosuppression (eyelid retraction ≥ 2 mm, exophthalmos ≥ 3 mm, inconstant or constant diplopia).
• Sight-Threatening GO: Presence of dysthyroid optic neuropathy (DON) or corneal breakdown.

Dermatological Evaluation:

A specialized dermatological examination focused on identifying thyroid dermopathy and thyroid acropachy. Suspected pretibial myxedema lesions were assessed for induration, hyperpigmentation, and peau d'orange characteristics. In equivocal cases, a 4-mm punch biopsy was performed to confirm the presence of extensive mucin (glycosaminoglycan) deposition in the reticular dermis via Alcian blue staining.

Serological Profiling:

Fasting venous blood samples were collected preoperatively. Assays were run for Thyroid-Stimulating Hormone (TSH), free Triiodothyronine (fT3), and free Thyroxine (fT4). Serum TRAb levels were measured using a third-generation competitive binding immunoassay.

Surgical Intervention and Histopathological Processing:

Patients underwent total or near-total thyroidectomy. Resected specimens were fixed in 10% neutral buffered formalin, serially sectioned, and stained with Hematoxylin and Eosin (H&E). Pathological classification differentiated between benign hyperplastic conditions (e.g., Graves' disease, nodular goiter) and malignant neoplasms (e.g., Papillary Thyroid Carcinoma, Follicular Carcinoma).

Statistical Analysis

Statistical analyses were performed using standardized software. Continuous variables were presented as mean ± standard deviation, and categorical variables as frequencies and percentages. The correlation between active TED, dermopathy, and specific histopathological entities was evaluated using the Chi-square ($\chi^2$) test. Differences in continuous variables (e.g., TRAb titers) between groups were assessed using the independent Student's t-test or Mann-Whitney U test, as appropriate. A p-value of < 0.05 was considered statistically significant.

Patient Demographics and Definitive Histopathology

The standardized cohort (N=85) demonstrated a strong female preponderance, consisting of 61 females (71.8%) and 24 males (28.2%). The overall mean age at the time of surgery was 52.4 ± 13.8 years. Final surgical histopathology revealed that 62.4% (n=53) of the patients had benign thyroid disease. Within this group, Graves' disease with diffuse hyperplasia was the most common finding (n=28), followed by multinodular goiter with lymphocytic thyroiditis (n=17) and Hashimoto's thyroiditis (n=8). Malignant pathology was identified in 37.6% (n=32) of the cohort. Papillary Thyroid Carcinoma (PTC) was the overwhelmingly dominant malignancy, representing 84.4% (n=27) of all cancer cases. Incidental papillary microcarcinomas (tumors ≤ 1 cm) were identified in 6 of the specimens primarily resected for presumed benign Graves' disease.

Table 1: Cohort Demographics and Surgical Histopathology

Ophthalmic Assessment and TED Severity

Preoperative ophthalmic examination identified signs of Thyroid Eye Disease in 48.2% (n=41) of the total cohort. Based on the EUGOGO classification system, 18 patients (21.2%) presented with mild GO, 21 patients (24.7%) with moderate-to-severe GO, and 2 patients (2.4%) exhibited sight-threatening GO due to compressive optic neuropathy. When assessing disease activity via the CAS, 30 patients (35.3% of the total cohort) demonstrated active GO (CAS ≥ 3). Patients with active GO reported significantly higher rates of spontaneous orbital pain, conjunctival redness, and eyelid swelling compared to those with inactive disease.

Dermatological Findings: Thyroid Dermopathy

Localized thyroid dermopathy (pretibial myxedema) was identified in 10 patients, representing 11.8% of the entire cohort. The clinical morphology varied from raised, indurated, non-pitting erythematous plaques to more diffuse, elephantiasic swelling of the anterior lower limbs.

A stark correlation was observed between ocular severity and dermatological involvement. All 10 patients exhibiting thyroid dermopathy concurrently suffered from active (CAS ≥ 3), moderate-to-severe, or sight-threatening TED. No instances of pretibial myxedema were observed in patients with mild GO or those entirely free of ocular involvement (p < 0.001).

Table 2: Extrathyroidal Clinical Manifestations (N=85)

Serological Correlation with Extrathyroidal Disease

Serum TRAb levels proved to be a highly sensitive biomarker for extrathyroidal disease severity. The mean preoperative TRAb titer for the entire cohort was 11.4 IU/L. However, patients stratified into the active, moderate-to-severe GO category exhibited dramatically elevated mean TRAb levels (28.7 ± 7.4 IU/L) compared to patients with mild GO (5.1 ± 2.3 IU/L) and those without GO (1.2 ± 0.8 IU/L). This difference was highly statistically significant (p < 0.001). Furthermore, the subgroup of 10 patients presenting with concurrent thyroid dermopathy demonstrated the highest absolute TRAb titers recorded in the study, with a mean of 34.6 ± 11.8 IU/L.

Correlation Between Extrathyroidal Signs and Surgical Pathology

Cross-tabulation of extrathyroidal clinical manifestations against definitive surgical pathology revealed distinct patterns. Active GO was disproportionately associated with benign autoimmune hyperplasia (Graves' disease). Of the 30 patients with active GO, 27 (90.0%) had benign surgical pathology, while only 3 (10.0%) had malignant pathology. Notably, in the 3 cases where active GO co-existed with a thyroid malignancy (all of which were Papillary Thyroid Carcinomas), histopathological mapping consistently demonstrated that the malignant foci were situated within a diffuse background of intense lymphocytic thyroiditis or hyperplastic autoimmune changes. Pure thyroid carcinomas arising in histologically normal, non-autoimmune background thyroid tissue were not associated with active GO or thyroid dermopathy in this cohort.

The intricate web of autoimmune responses in thyroid disease produces clinical phenotypes that span multiple organ systems. This study systematically mapped the relationships between ophthalmic activity, dermatological manifestations, serological markers, and definitive surgical histopathology, reinforcing the necessity of a multidisciplinary approach to complex thyroid disease.

Pathophysiological and Serological Correlations

The dominant extrathyroidal manifestation of autoimmune thyroiditis is Graves' orbitopathy. GO is caused by persistent, unregulated stimulation of TSHR-expressing orbital target cells, such as fibroblasts and pre-adipocytes. Our data firmly supports this mechanistic framework. We observed that serum TSHR-Ab, specifically stimulatory antibodies (TSAb), strongly correlate with the clinical activity and severity of GO [6]. Patients with active, moderate-to-severe GO demonstrated TRAb levels more than four times higher than those with mild disease.

Furthermore, levels of TRAb in subjects with recent-onset GO are directly correlated with clinical activity [4]. This serological correlation extends powerfully to dermatological findings. The 11.8% of our cohort presenting with pretibial myxedema exhibited the highest TRAb titers, underscoring that dermopathy is a late-stage hallmark of profound, systemically unchecked humoral autoimmunity. The dermal accumulation of GAGs mimics the retrobulbar process, driven by the same TSHR-reactive T-cell infiltration. Measurement of functional TSHR-Ab, especially TSAb, is clinically relevant for the differential diagnosis and management of GO [4, 6], as well as for assessing the risk of developing concurrent dermatological complications.

Standardized Clinical Assessment: EUGOGO and CAS

Managing the diverse clinical spectrum of TED requires rigorous, standardized grading to dictate therapeutic intervention. Disease activity is standardly assessed using the Clinical Activity Score (CAS), based on classical signs of inflammation including pain, redness, swelling, and impaired function [1]. In our surgical cohort, utilizing these criteria allowed for precise preoperative stratification. Active GO is defined clinically by a CAS of 3 or greater [1]. Identifying these 30 active patients preoperatively was paramount, as surgical trauma to the thyroid gland can transiently release stored autoantigens, potentially exacerbating orbital inflammation postoperatively. The EUGOGO classification system stratifies GO into mild, moderate-to-severe, and sight-threatening categories [2]. This classification directly guides medical therapy prior to, or in conjunction with, surgery. For instance, in moderate-to-severe active GO, intravenous glucocorticoids are generally more effective than oral administration. Recognizing patients in this category ensures they receive appropriate immunosuppression before proceeding to the operating room. Conversely, identifying sight-threatening GO requires immediate intervention; it can range from mild disease requiring observation, to sight-threatening disease requiring major drug therapy and orbital surgery [5].

Surgical Pathology and Extrathyroidal Disease

A primary objective of this study was to correlate these clinical findings with definitive surgical pathology. As anticipated, active TED and dermopathy were heavily concentrated in patients with benign, hyperplastic autoimmune pathology (Graves' disease). However, the intersection of TED with thyroid malignancy offers critical insights. Papillary carcinoma of the thyroid often has an excellent prognosis, particularly in young adults, even when lymph node involvement is present [3]. In our cohort, PTC was the dominant malignancy. Interestingly, we identified active TED in a small subset of patients primarily undergoing surgery for PTC. Detailed histopathological review of these cases revealed that the tumors did not occur in isolation; rather, they arose in a robust background of autoimmune lymphocytic thyroiditis. This suggests that the malignancy itself does not initiate the orbital or dermal inflammation, but the co-existing autoimmune microenvironment sustains the production of TRAbs. Surgical strategy must therefore be tailored. Therefore, relatively conservative surgery may be advised in low-risk patients, whereas total or subtotal thyroidectomy is required for advanced disease or when postoperative radioactive iodine is planned [3]. In patients with co-existing active TED and thyroid malignancy, total thyroidectomy serves a dual purpose: it achieves complete oncological clearance while simultaneously debulking the primary source of TSHR autoantigens, which may aid in the long-term stabilization of the orbitopathy.

Study Limitations

While this study benefits from a standardized multidisciplinary pathway, it possesses inherent limitations. As a surgical cohort from a tertiary center, there is an intrinsic referral bias toward more severe disease phenotypes, evidenced by the high rate (35.3%) of active TED and the substantial volume of malignant pathology. Patients with mild Graves' disease successfully managed on long-term antithyroid medications without surgical referral were naturally excluded. Additionally, while preoperative TRAb titers were extensively analyzed, longitudinal tracking of these titers post-thyroidectomy is necessary to fully quantify the long-term impact of surgical antigen removal on orbital and dermal remission.

Thyroid Eye Disease is a debilitating autoimmune condition often associated with thyroid dysfunction, leading to significant ocular and orbital morbidity. This research confirms a robust tripartite correlation between the clinical severity of TED, the manifestation of localized thyroid dermopathy, and elevated systemic TRAb levels. These extrathyroidal signs are fundamentally rooted in an autoimmune pathophysiological mechanism that manifests predominantly as benign hyperplastic thyroid disease on surgical histopathology. When TED is observed in the context of thyroid malignancy, it is invariably linked to a co-existing autoimmune background. Adherence to standardized assessment tools, such as the CAS and EUGOGO guidelines, is imperative for accurate risk stratification. Ultimately, optimal management of these complex patients relies on an integrated, multidisciplinary collaboration between Endocrinology, Ophthalmology, Dermatology, and Endocrine Surgery to navigate both the oncological and autoimmune facets of the disease.

1. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.
2. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021;185(4):G43-G67.
3. Cady B. Papillary carcinoma of the thyroid. Semin Surg Oncol. 1991;7(2):81-86.
4. Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest. 2021;44(4):703-712.
5. Hall AJH, Topliss DJ. Medical and surgical treatment of thyroid eye disease. Intern Med J. 2022;52(1):14-20.
6. Nicolì F, Lanzolla G, Mantuano M, Ionni I, Mazzi B, Leo M, et al. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical features of Graves' orbitopathy. J Endocrinol Invest. 2021;44(3):581-585.
7. Scarabosio A, Surico PL, Singh RB, Tereshenko V, Musa M, D'Esposito F, et al. Thyroid eye disease: advancements in orbital and ocular pathology management. J Pers Med. 2024;14(7):776.